Please assess the completion status of the following clinical trial:

Trial Title: Safety Study of Using Symlin Alongside Insulin in a Multiple Injection Port

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* male or female ages 18 and up~* utilizing a regimen of at least two injections daily of insulin and at least two injections daily of Symlin~* able to understand and sign an informed consent form and HIPPA form~* agrees to all study visits and procedures~* HbA1c between \>6.5 and \<9.0 (inclusive)~Exclusion Criteria:~* history or current diagnosis of chronic disease which in the view of the PI would interfere with adequate involvement in and completion of the requirements of the study~* history of malignancy with in the last five years of study entry (other than basal cell carcinoma)~* current use of any drugs that alter gastrointestinal motility (e.g., anticholinergic agents such as atropine), agents that slow intestinal absorption of nutrients (e.g. a-glucosidase inhibitors) or promotility agents (e.g. metaclopromide)~* any contraindication of Symlin or I-PORT according to the package labeling~* are female and pregnant, lactating or planning to become pregnant during the duration of the trial~* are poorly compliant with their current insulin and/or Symlin regimen, as defined by their HCP~* has history of known hypersensitivity to plastics or polymers~* treatment with any investigational drug within one month prior to enrollment~* myocardial infarction or stroke within six months prior to screening~* initiated use of Symlin pen or any Insulin pen in lieu of a vial in last 4 weeks (pen use is okay as long as they have been using it for at least 4 weeks prior to screening visit)~* female subjects of childbearing potential practicing inadequate birth control (adequate birth control is defined as using oral contraceptives, double barrier methods, Intrauterine devices, surgical sterilization or vasectomized partner)~* have confirmed diagnosis of gastroparesis~* have hypoglycemia unawareness

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- I-PORT (Type: ACTIVE_COMPARATOR): Treatment group
- standard injections (Type: ACTIVE_COMPARATOR): control group

Based on this trial design, predict the completion outcome and termination type (if applicable).